pyrazines has been researched along with Nausea in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaur, V; Swami, A | 1 |
| Aerts, JGJV; Baas, P; Cedrés, S; Fennell, DA; Gilligan, D; Kindler, H; Nakano, T; Nolan, L; Nowak, AK; Pachter, JA; Pavlakis, N; Scherpereel, A; Taylor, P; van Meerbeeck, JP; Weaver, DT | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| Chott, A; Formanek, M; Hauff, W; Jonak, C; Müllauer, L; Püspök, A; Raderer, M; Troch, M; Zielinski, CC | 1 |
| Chen, C; Eckhardt, SG; Pugh, TJ; Raben, D; Rabinovitch, R; Rusthoven, KE; Swing, R | 1 |
| Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z | 1 |
| Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Bo, J; Gao, C; Huang, W; Kang, W; Li, H; Li, J; Yu, L; Zhao, Y; Zhou, D | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB | 1 |
| Anderson, K; Hideshima, T; Mitsiades, C; Richardson, PG | 1 |
| Adjei, AA; Alberti, D; Alberts, SR; Binger, K; Bruzek, L; Dy, GK; Erlichman, C; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Marnocha, R; Pitot, HC; Thomas, JP; Tutsch, K; Wilding, G | 1 |
| Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ | 1 |
| Mikhail, N | 1 |
| Benson, L; Einzig, AI; Grove, WR; Lathia, CD; Roca, J; Sklarin, NT; Thomas, S; Wiernik, PH | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
| Choi, L; Denis, LJ; Eskens, FA; Foekens, JA; Harris, AL; Levitt, NC; Nakajima, M; O'Byrne, KJ; Owen, SJ; Propper, DJ; Steward, WP; Talbot, DC; Verweij, J; Wilner, S; Wood, JM | 1 |
| De Baere, H; De Leeuw, I; Decraene, P; Lemmens, P; Verhaegen, H | 1 |
| Caputo, G; Emanueli, A; Molari, E; Pirola, LC | 1 |
| Paterson, JW; Richards, AJ; Walker, SR | 1 |
4 review(s) available for pyrazines and Nausea
| Article | Year |
|---|---|
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Diarrhea; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nausea; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2017 |
Proteasome inhibition in hematologic malignancies.
Topics: Asthenia; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Diarrhea; Hematologic Neoplasms; Humans; Multienzyme Complexes; Nausea; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis; Treatment Outcome | 2004 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
A new anti-asthmatic drug (ICI 58 301): blood levels and spirometry.
Topics: Acetamides; Adult; Asthma; Cyclic AMP; Female; Humans; Male; Middle Aged; Nausea; Phosphoric Monoester Hydrolases; Pyrazines; Spirometry; Time Factors; Triazoles | 1971 |
16 trial(s) available for pyrazines and Nausea
| Article | Year |
|---|---|
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Diarrhea; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nausea; Neurofibromin 2; Pleural Neoplasms; Pyrazines; Sulfonamides; Treatment Outcome | 2019 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
A phase II study of bortezomib in patients with MALT lymphoma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Nausea; Nervous System Diseases; Pyrazines; Treatment Outcome | 2009 |
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Colorado; Combined Modality Therapy; Diarrhea; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Palliative Care; Pyrazines; Radiography | 2010 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; I-kappa B Proteins; Male; Middle Aged; Nausea; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting | 2005 |
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia | 2007 |
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting | 2008 |
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbamates; Central Nervous System Diseases; Drug Tolerance; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Pyridines | 1997 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Exanthema; Female; Humans; Hydroxamic Acids; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Musculoskeletal Diseases; Nausea; Neoplasms; Protease Inhibitors; Pyrazines; Sulfonamides; Treatment Outcome | 2001 |
Glipizide, a new sulfonylurea in the treatment of diabetes mellitus. Summary of clinical experience in 1064 cases.
Topics: Administration, Oral; Adult; Aged; Blood Cell Count; Blood Glucose; Blood Proteins; Cholesterol; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus; Drug Eruptions; Female; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nausea; Prothrombin Time; Pyrazines; Sulfonylurea Compounds; Tolbutamide; Transaminases; Vomiting | 1972 |
3 other study(ies) available for pyrazines and Nausea
| Article | Year |
|---|---|
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Bortezomib (velcade) for multiple myeloma.
Topics: Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Economics, Pharmaceutical; Fees, Pharmaceutical; Humans; Multiple Myeloma; Nausea; Pyrazines | 2003 |
An open comparative study of the efficacy and tolerance of a new antidiabetic agent: glipizide.
Topics: Blood Glucose; Chlorpropamide; Cyclohexanes; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Nausea; Phenformin; Pyrazines; Sulfonylurea Compounds | 1973 |